Institute for Follicular Lymphoma Innovation Welcomes New Executive Partners in a Bold Move The Institute for Follicular Lymphoma Innovation has appointed Mehrdad Mobasher and Carol O'Hear as Executive Partners, enhancing its leadership team for innovation.

Institute for Follicular Lymphoma Innovation Welcomes New Executive Partners in a Bold Move #United_States #Diamond_Bar,_California #IFLI #Mehrdad_Mobasher #Carol_O'Hear

Verismo Therapeutics Advances Follicular Lymphoma Treatment in CELESTIAL-301 Trial Verismo Therapeutics has treated its first follicular lymphoma patient in the CELESTIAL-301 trial, enhancing collaboration with IFLI to explore new therapeutic options.

Verismo Therapeutics Advances Follicular Lymphoma Treatment in CELESTIAL-301 Trial #USA #Philadelphia #IFLI #Verismo_Therapeutics #CELESTIAL-301

CIT Therapeutics and IFLI Launch Collaboration for Innovative Cancer Treatments CIT Therapeutics collaborates with IFLI to advance innovative therapies for follicular lymphoma, securing $2.5 million for clinical development.

CIT Therapeutics and IFLI Launch Collaboration for Innovative Cancer Treatments #United_States #cancer_therapies #Diamond_Bar #IFLI #CIT_Therapeutics

Verismo Therapeutics Partners with IFLI to Boost SynKIR™-310 for Follicular Lymphoma Treatment Verismo Therapeutics announces a strategic investment partnership with IFLI to enhance development of SynKIR™-310 aimed at treating follicular lymphoma.

Verismo Therapeutics Partners with IFLI to Boost SynKIR™-310 for Follicular Lymphoma Treatment #USA #Philadelphia #IFLI #Verismo_Therapeutics #SynKIR™-310

PeproMene Bio and IFLI Announce $11 Million Investment for Innovative Lymphoma Treatment PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation have announced an $11 million investment to advance the PMB-CT01 treatment for relapsed or refractory follicular lymphoma.

PeproMene Bio and IFLI Announce $11 Million Investment for Innovative Lymphoma Treatment #USA #Irvine,_California #PeproMene_Bio #IFLI #PMB-CT01

PeproMene Bio Secures $11 Million Investment for Innovative CAR-T Therapy Advancement PeproMene Bio, Inc. has secured an $11 million investment to advance PMB-CT01, a CAR T cell therapy targeted at relapsed/refractory follicular lymphoma, following encouraging initial results.

PeproMene Bio Secures $11 Million Investment for Innovative CAR-T Therapy Advancement #USA #Irvine #PeproMene_Bio #IFLI #PMB-CT01

PeproMene Bio and IFLI Invest $11 Million for Promising Lymphoma Therapy in Patients PeproMene Bio announces an $11 million investment to enhance the development of PMB-CT01, a CAR T-cell therapy for lymphoma patients, following promising trial results.

PeproMene Bio and IFLI Invest $11 Million for Promising Lymphoma Therapy in Patients #United_States #Irvine #PeproMene_Bio #IFLI #PMB-CT01